Lyell Wealth Management LP Sells 315 Shares of Merck & Co., Inc. $MRK

Lyell Wealth Management LP lessened its stake in Merck & Co., Inc. (NYSE:MRK) by 5.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,224 shares of the company’s stock after selling 315 shares during the period. Lyell Wealth Management LP’s holdings in Merck & Co., Inc. were worth $414,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in MRK. Little House Capital LLC boosted its stake in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after acquiring an additional 308 shares during the last quarter. Semus Wealth Partners LLC boosted its stake in shares of Merck & Co., Inc. by 8.2% during the 1st quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock worth $452,000 after acquiring an additional 382 shares during the last quarter. Longfellow Investment Management Co. LLC boosted its stake in shares of Merck & Co., Inc. by 20.4% during the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after acquiring an additional 3,282 shares during the last quarter. Quilter Plc boosted its stake in shares of Merck & Co., Inc. by 5.6% during the 1st quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock worth $105,988,000 after acquiring an additional 62,933 shares during the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in shares of Merck & Co., Inc. by 9.8% during the 2nd quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after acquiring an additional 79,529 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the topic of several analyst reports. Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Wells Fargo & Company dropped their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Finally, Citigroup initiated coverage on shares of Merck & Co., Inc. in a research note on Monday, October 13th. They set a “neutral” rating and a $95.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $104.33.

Merck & Co., Inc. Trading Up 1.8%

Shares of Merck & Co., Inc. stock opened at $86.30 on Tuesday. The company has a market capitalization of $215.56 billion, a P/E ratio of 13.30, a P/E/G ratio of 0.93 and a beta of 0.37. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42. The company has a fifty day moving average of $84.03 and a 200 day moving average of $81.35. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $109.17.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.10. The company had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.